Nutritional considerations with antiobesity medications

被引:13
|
作者
Almandoz, Jaime P. [1 ]
Wadden, Thomas A. [2 ]
Tewksbury, Colleen [3 ]
Apovian, Caroline M. [4 ]
Fitch, Angela [5 ]
Ard, Jamy D. [6 ,7 ]
Li, Zhaoping [8 ]
Richards, Jesse [9 ]
Butsch, W. Scott [10 ]
Jouravskaya, Irina [11 ]
Vanderman, Kadie S. [12 ]
Neff, Lisa M. [11 ,13 ]
机构
[1] Univ Texas, Southwestern Med Ctr, Div Endocrinol, Dallas, TX USA
[2] Univ Penn, Dept Psychiat, Philadelphia, PA USA
[3] Univ Penn, Dept Surg, Philadelphia, PA USA
[4] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA USA
[5] Knownwell, Boston, MA USA
[6] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA
[7] Wake Forest Sch Med, Dept Med, Winston Salem, NC USA
[8] Univ Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA USA
[9] Univ Oklahoma, Sch Med, Dept Internal Med, Tulsa, OK USA
[10] Cleveland Clin, Bariatr & Metab Inst, Cleveland, OH USA
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Syneos Hlth, Morrisville, NC USA
[13] Eli Lilly & Co, Lilly Corp Ctr, Global Med Affairs Obes, Indianapolis, IN 46225 USA
关键词
PEPTIDE-1 RECEPTOR AGONISTS; CARDIOVASCULAR RISK-FACTORS; LONG-TERM PERSISTENCE; BINGE-EATING DISORDER; WEIGHT-LOSS; CLINICAL-PRACTICE; AMERICAN ASSOCIATION; PRACTICE GUIDELINES; OBESITY MANAGEMENT; FOOD-INTAKE;
D O I
10.1002/oby.24067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of >= 15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.
引用
收藏
页码:1613 / 1631
页数:19
相关论文
共 50 条
  • [41] Should the Same Safety Scrutiny of Antiobesity Medications be Applied to Other Chronic Usage Drugs?
    Halpern, Bruno
    Mancini, Marcio C.
    OBESITY, 2020, 28 (07) : 1171 - 1172
  • [42] Lifestyle Intervention Requirements for Novel Antiobesity Medications-Necessary Adjunct or Harmful Gatekeeper?
    Golovaty, Ilya
    Hagan, Scott
    JAMA INTERNAL MEDICINE, 2025, 185 (03) : 255 - 256
  • [43] Cardiovascular Considerations for Stimulant Class Medications
    Hammerness, Paul
    Berger, Amy
    Angelini, Michael C.
    Wilens, Timothy E.
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2022, 31 (03) : 437 - 448
  • [44] Pharmacogenomic considerations for medications in the perioperative setting
    Jhun, Ellie H.
    Apfelbaum, Jeffrey L.
    Dickerson, David M.
    Shahul, Sajid
    Knoebel, Randall
    Danahey, Keith
    Ratain, Mark J.
    O'Donnell, Peter H.
    PHARMACOGENOMICS, 2019, 20 (11) : 813 - 827
  • [45] An Efficient Approach to Expand Equitable Access to Antiobesity Medications: Deprescribing After Weight Loss Plateau
    Kim, David D.
    Fendrick, A. Mark
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (08): : 348 - 350
  • [46] Antiobesity Medications in Patients With Heart Failure A Clinical Protocol and Preliminary Single-Center Experience
    Hussani, Sureya F.
    Nguyen, Kelly
    Yu, Ka man
    Sinha, Darius
    Vest, Amanda R.
    JACC-HEART FAILURE, 2024, 13 (02) : 375 - 380
  • [47] Response to "Early- and later-stage persistence with antiobesity medications: a retrospective cohort study"
    Fitch, Angela
    Huett-Garcia, Amber
    OBESITY, 2024, 32 (06) : 1039 - 1040
  • [48] Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
    Acosta, Andres
    Camilleri, Michael
    Abu Dayyeh, Barham
    Calderon, Gerardo
    Gonzalez, Daniel
    McRae, Alison
    Rossini, William
    Singh, Sneha
    Burton, Duane
    Clark, Matthew M.
    OBESITY, 2021, 29 (04) : 662 - 671
  • [49] Socioeconomic status and use of obesogenic and antiobesity medications in the United States: A population-based study
    Lyu, Beini
    Chang, Alex R.
    Inker, Lesley A.
    Selvin, Elizabeth
    Grams, Morgan E.
    Shin, Jung-Im
    LANCET REGIONAL HEALTH-AMERICAS, 2022, 11
  • [50] Adulteration of the Herbal Weight Loss Products by the Illegal Addition of Synthetic Antiobesity Medications: A Pilot Study
    Firozian, Farzin
    Nili-Ahmadabadi, Amir
    Moradkhani, Shirin
    Moulaei, Miad
    Fasihi, Zohreh
    Ahmadimoghaddam, Davoud
    JOURNAL OF OBESITY, 2021, 2021